Abstract
Alzheimer’s disease (AD) represents a neurological disorder, which is caused by enzymatic degradation of an amyloid precursor protein into short peptide fragments that undergo association to form insoluble plaques. Preliminary studies suggest that cyanobacterial extracts, especially the light-harvesting protein phycocyanin, may provide a means to control the progression of the disease. However, the molecular mechanism of disease control remains elusive. In the present study, intact hexameric phycocyanin was isolated and crystallized from the cyanobacterium Leptolyngbya sp. N62DM, and the structure was solved to a resolution of 2.6 A. Molecular docking studies show that the phycocyanin αβ- dimer interacts with the enzyme β-secretase, which catalyzes the proteolysis of the amyloid precursor protein to form plaques. The molecular docking studies suggest that the interaction between phycocyanin and β-secretase is energetically more favorable than previously reported inhibitor-β-secretase interactions. Transgenic Caenorhabditis elegans worms, with a genotype to serve as an AD-model, were significantly protected by phycocyanin. Therefore, the present study provides a novel structure-based molecular mechanism of phycocyanin-mediated therapy against AD.
Keywords: Alzheimer's, amyloid precursor protein, β-secretase, cyanobacteria, phycocyanin.
CNS & Neurological Disorders - Drug Targets
Title:Crystal Structure and Interaction of Phycocyanin with β-Secretase: A Putative Therapy for Alzheimer's Disease
Volume: 13 Issue: 4
Author(s): Niraj Kumar Singh, Syed S. Hasan, Jitendra Kumar, Isha Raj, Amrin A. Pathan, Asha Parmar, Shazi Shakil, Samudrala Gourinath and Datta Madamwar
Affiliation:
Keywords: Alzheimer's, amyloid precursor protein, β-secretase, cyanobacteria, phycocyanin.
Abstract: Alzheimer’s disease (AD) represents a neurological disorder, which is caused by enzymatic degradation of an amyloid precursor protein into short peptide fragments that undergo association to form insoluble plaques. Preliminary studies suggest that cyanobacterial extracts, especially the light-harvesting protein phycocyanin, may provide a means to control the progression of the disease. However, the molecular mechanism of disease control remains elusive. In the present study, intact hexameric phycocyanin was isolated and crystallized from the cyanobacterium Leptolyngbya sp. N62DM, and the structure was solved to a resolution of 2.6 A. Molecular docking studies show that the phycocyanin αβ- dimer interacts with the enzyme β-secretase, which catalyzes the proteolysis of the amyloid precursor protein to form plaques. The molecular docking studies suggest that the interaction between phycocyanin and β-secretase is energetically more favorable than previously reported inhibitor-β-secretase interactions. Transgenic Caenorhabditis elegans worms, with a genotype to serve as an AD-model, were significantly protected by phycocyanin. Therefore, the present study provides a novel structure-based molecular mechanism of phycocyanin-mediated therapy against AD.
Export Options
About this article
Cite this article as:
Singh Kumar Niraj, Hasan S. Syed, Kumar Jitendra, Raj Isha, Pathan A. Amrin, Parmar Asha, Shakil Shazi, Gourinath Samudrala and Madamwar Datta, Crystal Structure and Interaction of Phycocyanin with β-Secretase: A Putative Therapy for Alzheimer's Disease, CNS & Neurological Disorders - Drug Targets 2014; 13 (4) . https://dx.doi.org/10.2174/1871527313666140228114456
DOI https://dx.doi.org/10.2174/1871527313666140228114456 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Methylation in the Pathogenesis of Systemic Lupus Erythematosus
Current Pharmacogenomics Bactericidal Activity of a Cationic Peptide on Neisseria meningitidis
Infectious Disorders - Drug Targets Synthesis, Antimicrobial Evaluation and Docking Study of Novel Thiosemicarbazone Clubbed with 1,2,3-Triazoles
Current Bioactive Compounds Role of Dietary Polyphenols in Attenuating Brain Edema and Cell Swelling in Cerebral Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Current Advances in the Identification and Characterization of Putative Drug and Vaccine Targets in the Bacterial Genomes
Current Topics in Medicinal Chemistry Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer
Current Cancer Drug Targets MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Adjunctive Immunotherapy of Mycobacterial Infections
Current Pharmaceutical Design Cell Adhesion Molecules in Gene and Cell Therapy Approaches for Nervous System Repair
Current Gene Therapy Prokaryotic Substrate-Binding Proteins as Targets for Antimicrobial Therapies
Current Drug Targets The Role of Universal Stress Proteins in Bacterial Infections
Current Medicinal Chemistry Antifungal Prophylaxis in the Preterm Infant
Current Pediatric Reviews Isolation of <i>Morganella Morganii</i> and <i>Providencia</i> Species from Clinical Samples in a Tertiary Care Hospital in North India
Infectious Disorders - Drug Targets The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Oral Tolerance and TGF-β -Producing Cells
Inflammation & Allergy - Drug Targets (Discontinued) Identification of Antifungal Agents Using Combinatorial Approach: An Overview$
Current Medicinal Chemistry - Anti-Infective Agents Carbapenem Resistance Among Common <i>Enterobacteriaceae</i> Clinical Isolates in Part of North-East India
Anti-Infective Agents Antimicrobial Effect of Garlic (Allium sativum)
Recent Patents on Anti-Infective Drug Discovery